Sprint Bioscience, a Stockholm, Sweden-based company focusing on early cancer drug discovery using fragment-based methods, has raised start up capital from ALMI Invest and Entreprenörsfonden.
Sprint Bioscience offers a platform for fragment-based drug discovery comprising protein expression and purification, fragment screening, high-throughput X-ray crystallography and full expansion of fragments into a patented lead series.
The company, which was founded in 2009 by Prof. Pär Nordlund and Dr. Anders Åberg, offers both services and research to large and small pharmaceutical companies.
FinSMEs
25/11/2010